125_51.pdf 1.19 MB
A successful rechallenge with cetuximab for a case with metastatic rectal cancer
A 55-year-old man who had been diagnosed with rectal cancer with multiple liver metastases and lymph node metastases on colonoscopy and computed tomography (CT) was referred to Okayama University Hospital for treatment. Based on the diagnosis of non-curative rectal cancer, we planned to perform systematic chemotherapy after surgical resection. We performed a low anterior resection of a 36×35 mm upper rectal moderately differentiated adenocarcinoma with wil-type KRAS. After the resection, a FOLFIRI regimen with cetuximab was given as the first-line chemotherapy. Although metastatic lesions in the liver showed shrinkage, we decided to switch regimens because of intolerable adverse events. A modified FOLFOX6 regimen with bevacizumab was administered as the second-line treatment. There were no signs of disease progression until eight months later, when positron emission tomography (PET)/CT scans revealed that the new metastatic lesions appeared. As the third-line treatment, an irinotecan with cetuximab regimen was administered, leading to a good response for over 12 months. We experienced a successful rechallenge with cetuximab for a case with metastatic rectal cancer. For patients with wild-type KRAS colorectal cancer, rechallenge with cetuximab-based chemotherapy can be an effective therapeutic option.
|Publication Title Alternative||
Journal of Okayama Medical Association
Okayama Medical Association
1) Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, et al. : Cetuximab rechallenge in metastatic colorectal cancer patients : how to come away from acquired resistance? Ann Oncol (2012) 23, 2313-2318.
2) Erlichman C, Fine S, Wong A, Elhakim T : A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol (1988) 6, 469-475.
3) O'Conell MJ : A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group Study. Cancer (1989) 63, 1026-1030.
4) Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr : Randomized comparison of two schedule of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 12, 14-20.
5) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer : evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol (1992) 10, 896-903.
6) Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL : Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med (2000) 343, 905-914.
7) Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P : Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer : A multicentre randomized trial. Lancet (2000) 355, 1041-1047.
8) Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S : Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer : a North American Intergroup Trial. J Clin Oncol (2006) 20, 3347-3353.
9) Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, et al. : Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer : A multicenter study of the groppo oncologico dell'italia meridionale. J Clin Oncol (2005) 23, 4866-4875.
10) Grothey A, Sargent D : Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol (2005) 23, 9441-9442.
11) Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, et al. : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 360, 1408-1417.
12) Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, et al. : Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer : Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol (2011) 29, 2011-2019.
13) 大腸癌治療ガイドライン 医師用, 大腸癌研究会編, 金原出版株式会社, 東京（2010）pp16-29, 53.
14) Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, et al. ; for the CORRECT Study Group : Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2013) 381, 303-312.
Copyright (c) 2013 岡山医学会
|Eprints Journal Name||